You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameS-Ethylisothiourea
Accession NumberDB02539  (EXPT02886)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS number2986-20-1
WeightAverage: 104.174
Monoisotopic: 104.040818956
Chemical FormulaC3H8N2S
InChI KeyVFIZBHJTOHUOEK-UHFFFAOYSA-N
InChI
InChI=1S/C3H8N2S/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)
IUPAC Name
(ethylsulfanyl)methanimidamide
SMILES
CCSC(N)=N
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Nitric oxide synthase, inducibleProteinunknownNot AvailableHumanP35228 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with S-Ethylisothiourea.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with S-Ethylisothiourea.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with S-Ethylisothiourea.Approved
adipiplonThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with S-Ethylisothiourea.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with S-Ethylisothiourea.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with S-Ethylisothiourea.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with S-Ethylisothiourea.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with S-Ethylisothiourea.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Azaperone.Vet Approved
AzelastineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with S-Ethylisothiourea.Illicit
BenperidolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with S-Ethylisothiourea.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with S-Ethylisothiourea.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with S-Ethylisothiourea.Approved, Investigational
BuprenorphineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with S-Ethylisothiourea.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with S-Ethylisothiourea.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with S-Ethylisothiourea.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with S-Ethylisothiourea.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with S-Ethylisothiourea.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with S-Ethylisothiourea.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with S-Ethylisothiourea.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with S-Ethylisothiourea.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with S-Ethylisothiourea.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with S-Ethylisothiourea.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with S-Ethylisothiourea.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with S-Ethylisothiourea.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with S-Ethylisothiourea.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with S-Ethylisothiourea.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with S-Ethylisothiourea.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with S-Ethylisothiourea.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with S-Ethylisothiourea.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with S-Ethylisothiourea.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with S-Ethylisothiourea.Approved
DapoxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with S-Ethylisothiourea.Approved
DesipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with S-Ethylisothiourea.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with S-Ethylisothiourea.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with S-Ethylisothiourea.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with S-Ethylisothiourea.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with S-Ethylisothiourea.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with S-Ethylisothiourea.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with S-Ethylisothiourea.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with S-Ethylisothiourea.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with S-Ethylisothiourea.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with S-Ethylisothiourea.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with S-Ethylisothiourea.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with S-Ethylisothiourea.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with S-Ethylisothiourea.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with S-Ethylisothiourea.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with S-Ethylisothiourea.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with S-Ethylisothiourea.Approved
EthanolS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with S-Ethylisothiourea.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with S-Ethylisothiourea.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with S-Ethylisothiourea.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with S-Ethylisothiourea.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with S-Ethylisothiourea.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with S-Ethylisothiourea.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with S-Ethylisothiourea.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with S-Ethylisothiourea.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with S-Ethylisothiourea.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with S-Ethylisothiourea.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with S-Ethylisothiourea.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with S-Ethylisothiourea.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with S-Ethylisothiourea.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with S-Ethylisothiourea.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with S-Ethylisothiourea.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with S-Ethylisothiourea.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with S-Ethylisothiourea.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with S-Ethylisothiourea.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with S-Ethylisothiourea.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with S-Ethylisothiourea.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with S-Ethylisothiourea.Approved
HydrocodoneS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with S-Ethylisothiourea.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved
IloperidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with S-Ethylisothiourea.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with S-Ethylisothiourea.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with S-Ethylisothiourea.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with S-Ethylisothiourea.Approved
LevocabastineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with S-Ethylisothiourea.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with S-Ethylisothiourea.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with S-Ethylisothiourea.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with S-Ethylisothiourea.Approved
LofentanilThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with S-Ethylisothiourea.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with S-Ethylisothiourea.Approved
Lu AA21004The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with S-Ethylisothiourea.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with S-Ethylisothiourea.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with S-Ethylisothiourea.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with S-Ethylisothiourea.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with S-Ethylisothiourea.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with S-Ethylisothiourea.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with S-Ethylisothiourea.Approved
MethotrimeprazineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with S-Ethylisothiourea.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with S-Ethylisothiourea.Approved
MetyrosineS-Ethylisothiourea may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with S-Ethylisothiourea.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved, Investigational
MirtazapineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with S-Ethylisothiourea.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with S-Ethylisothiourea.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with S-Ethylisothiourea.Approved
NefazodoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with S-Ethylisothiourea.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with S-Ethylisothiourea.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with S-Ethylisothiourea.Approved
OpiumThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Opium.Approved, Illicit
OrphenadrineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with S-Ethylisothiourea.Approved
OxetacaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with S-Ethylisothiourea.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with S-Ethylisothiourea.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with S-Ethylisothiourea.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with S-Ethylisothiourea.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with S-Ethylisothiourea.Approved
ParaldehydeS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with S-Ethylisothiourea.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with S-Ethylisothiourea.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved
PerazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with S-Ethylisothiourea.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with S-Ethylisothiourea.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with S-Ethylisothiourea.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with S-Ethylisothiourea.Approved
PipamperoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pomalidomide.Approved
PramipexoleS-Ethylisothiourea may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with S-Ethylisothiourea.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with S-Ethylisothiourea.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with S-Ethylisothiourea.Approved
PrimidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with S-Ethylisothiourea.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with S-Ethylisothiourea.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with S-Ethylisothiourea.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with S-Ethylisothiourea.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with S-Ethylisothiourea.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with S-Ethylisothiourea.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with S-Ethylisothiourea.Approved
RacloprideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with S-Ethylisothiourea.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with S-Ethylisothiourea.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with S-Ethylisothiourea.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with S-Ethylisothiourea.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Romifidine.Vet Approved
RopiniroleS-Ethylisothiourea may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with S-Ethylisothiourea.Approved
RotigotineS-Ethylisothiourea may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with S-Ethylisothiourea.Approved
Sage 547The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with S-Ethylisothiourea.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with S-Ethylisothiourea.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved
StiripentolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with S-Ethylisothiourea.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with S-Ethylisothiourea.Approved
SuvorexantS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Approved
TasimelteonThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with S-Ethylisothiourea.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetrodotoxin.Investigational
ThalidomideS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with S-Ethylisothiourea.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with S-Ethylisothiourea.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with S-Ethylisothiourea.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with S-Ethylisothiourea.Approved
TiagabineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with S-Ethylisothiourea.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with S-Ethylisothiourea.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with S-Ethylisothiourea.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with S-Ethylisothiourea.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with S-Ethylisothiourea.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with S-Ethylisothiourea.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with S-Ethylisothiourea.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with S-Ethylisothiourea.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with S-Ethylisothiourea.Approved
ZolazepamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zolazepam.Vet Approved
ZolpidemS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with S-Ethylisothiourea.Approved
ZotepineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with S-Ethylisothiourea.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9417
Blood Brain Barrier+0.8566
Caco-2 permeable-0.6514
P-glycoprotein substrateNon-substrate0.7429
P-glycoprotein inhibitor INon-inhibitor0.9487
P-glycoprotein inhibitor IINon-inhibitor0.9516
Renal organic cation transporterNon-inhibitor0.8246
CYP450 2C9 substrateNon-substrate0.7953
CYP450 2D6 substrateNon-substrate0.7215
CYP450 3A4 substrateNon-substrate0.8339
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9494
CYP450 2D6 inhibitorInhibitor0.5903
CYP450 2C19 inhibitorNon-inhibitor0.9319
CYP450 3A4 inhibitorNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8695
Ames testNon AMES toxic0.9145
CarcinogenicityNon-carcinogens0.6958
BiodegradationNot ready biodegradable0.8293
Rat acute toxicity2.8731 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9836
hERG inhibition (predictor II)Non-inhibitor0.9611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility4.77 mg/mLALOGPS
logP0.03ALOGPS
logP0.67ChemAxon
logS-1.3ALOGPS
pKa (Strongest Basic)10.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.87 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity39.78 m3·mol-1ChemAxon
Polarizability10.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isothioureas. These are organic compounds containing the isothiourea group, with the general structure R1SC(=NR2)N(R3)R4 (R1,R2,R3,R4=H, alkyl, aryl).
KingdomOrganic compounds
Super ClassOrganosulfur compounds
ClassIsothioureas
Sub ClassNot Available
Direct ParentIsothioureas
Alternative Parents
Substituents
  • Isothiourea
  • Sulfenyl compound
  • Carboximidamide
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Imine
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23